Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
Rhea-AI Summary
Replimune (NASDAQ: REPL) announced FDA acceptance for review of its resubmitted Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma.
The FDA deemed the filing a complete, class 1 response, set a goal decision date of August 2, 2026, and plans an advisory committee meeting in late July. The resubmission seeks accelerated approval based on IGNYTE trial data in patients progressing on prior anti-PD-1 therapy.
Positive
- FDA accepted RP1 BLA resubmission as a complete, class 1 response
- Target FDA decision (PDUFA) date set for August 2, 2026
- FDA plans advisory committee meeting in late July 2026
- Resubmission seeks accelerated approval in advanced melanoma
- IGNYTE trial supports RP1 plus nivolumab in post–anti-PD-1 patients
Negative
- Regulatory outcome for RP1 remains pending with no approval yet granted
- Upcoming advisory committee adds an additional regulatory review step
News Market Reaction – REPL
In the Jun 26 session, REPL gained 4.49%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.4% during that session. Argus tracked a trough of -15.3% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 31 | Clinical data update | Positive | +3.6% | Final first-in-human RP2 data showed responses and durable disease control. |
| May 29 | BLA resubmission plan | Positive | +85.7% | FDA agreed to urgent RP1 BLA resubmission path supported by IGNYTE trial data. |
| Apr 27 | ASCO presentations | Positive | +10.7% | Multiple planned ASCO presentations with RP1 and RP2 survival and efficacy updates. |
| Apr 10 | FDA CRL | Negative | -64.3% | FDA Complete Response Letter for RP1 BLA in advanced melanoma following review. |
| Mar 02 | Investor conferences | Neutral | -6.4% | Participation in two March investor conferences with a webcasted fireside chat. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
REPL has typically moved sharply in the direction implied by major FDA and clinical milestones, with only occasional divergence on routine conference news.
Key Terms
biologics license application regulatory
oncolytic immunotherapies medical
accelerated approval regulatory
advisory committee meeting regulatory
anti-pd-1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FDA decision expected by August 2, 2026
WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal date of August 2, 2026, and has notified the company to expect an advisory committee meeting in late July.
“We are pleased that the FDA has demonstrated urgency in reconsidering the RP1 BLA with an expeditious action date in recognition of the significant unmet need for advanced melanoma patients and support from the broader melanoma community,” said Sushil Patel, Ph.D., CEO of Replimune. “We look forward to a productive scientific and clinical discussion on the risk/benefit profile of RP1 in this difficult to treat setting.”
The resubmission seeks accelerated approval of RP1 in advanced melanoma based on data from the IGNYTE clinical trial, which evaluated RP1 combined with nivolumab in patients with confirmed progression on an anti-PD-1 containing regimen.
About Advanced Melanoma
Melanoma is the fifth most common cancer in the United States, with approximately 112,000 new cases estimated in 2026 and the most lethal form of skin cancer, accounting for nearly 8,500 deaths annually. Melanoma is considered advanced when the cancer has spread beyond the primary tumor. Standard of care therapy includes immune checkpoint blockade, to which approximately half of patients will not respond or will progress after treatment, leaving a significant population in need of effective therapeutic alternatives.
About RP1
RP1 (vusolimogene oderparepvec) is Replimune's lead product candidate, based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R⁻) and GM-CSF. RP1 is designed to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including the status of the FDA review of our BLA for RP1 or potential approval of such BLA, the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates, the regulatory review process and timing of potential product approval, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to the outcome of FDA’s review process, our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of a global pandemic and related public health issues and the ongoing political and military conflicts, including trade conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
